keyword
MENU ▼
Read by QxMD icon Read
search

Heart failure clinical trial

keyword
https://www.readbyqxmd.com/read/28727672/cardiac-rehabilitation-in-patients-with-left-ventricular-assist-device-a-systematic-review-and-meta-analysis
#1
Toufik Mahfood Haddad, Alok Saurav, Aiman Smer, Muhammad S Azzouz, Abhilash Akinapelli, Mark A Williams, Venkata M Alla
PURPOSE: Exercise-based cardiac rehabilitation (EBCR) has been demonstrated to improve functional capacity in heart failure (HF). However, there are limited data on the effect of EBCR in patients with advanced HF and left ventricular assist devices (LVADs). This meta-analysis sought to evaluate the effects of EBCR on functional capacity in patients with LVAD. METHODS: PubMed, Web of Science, CINAHL, and Cochrane Library databases were searched for randomized studies assessing the impact of EBCR in patients following LVAD implantation compared with standard therapy (ST)...
July 19, 2017: Journal of Cardiopulmonary Rehabilitation and Prevention
https://www.readbyqxmd.com/read/28726428/-a-present-view-on-ivabradine-in-the-therapy-of-cardiovascular-diseases
#2
Jiří Slíva
Cardiovascular illnesses belong to diseases with the highest prevalence. They are also the most predominant reason of death in the vast majority of European countries. Hence, the offer of effective treatment of these dis-eases is absolutely crucial. This text focuses on the current therapeutical use of ivabradine in its approved indications - chronic stable angina pectoris and chronic heart failure - in the context of so far published relevant clinical trials.Key words: angina pectoris - bradines - heart failure - If current - ischemic heart disease - ivabradine...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28725326/comparison-of-clopidogrel-with-prasugrel-and-ticagrelor-in-patients-with-acute-coronary-syndrome-clinical-outcomes-from-the-national-cardiovascular-database-action-registry
#3
Mohamed Khayata, Joseph N Gabra, M Farhan Nasser, George I Litman, Shyam Bhakta, Rupesh Raina
BACKGROUND: We aimed to compare the clinical outcomes of clopidogrel, prasugrel, and ticagrelor in clinical practice using the National Cardiovascular Database ACTION Registry(®). Treatment guidelines for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention recommend dual antiplatelet therapy (DAPT) for 12 months. Few clinical trials have compared the safety and efficacy of clopidogrel with that of newer antiplatelet therapies. METHODS: A retrospective study of patients hospitalized for ACS at Cleveland Clinic Akron General was conducted...
June 2017: Cardiology Research
https://www.readbyqxmd.com/read/28724329/new-heart-failure-pharmacotherapy-in-clinical-trials-a-hope-in-progress
#4
Ahmed Selim, Ronald Zolty, Yiannis S Chatzizisis
No abstract text is available yet for this article.
July 20, 2017: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/28724134/association-of-implantable-cardioverter-defibrillators-with-survival-in-patients-with-and-without-improved-ejection-fraction-secondary-analysis-of-the-sudden-cardiac-death-in-heart-failure-trial
#5
Selcuk Adabag, Kristen K Patton, Alfred E Buxton, Thomas S Rector, Kristine E Ensrud, Kairav Vakil, Wayne C Levy, Jeanne E Poole
Importance: Improvement in left ventricular ejection fraction (EF) to >35% occurs in many patients with reduced EF at baseline. To our knowledge, whether implantable cardioverter defibrillator (ICD) therapy improves survival for these patients is unknown. Objective: To examine the efficacy of ICD therapy in reducing risk of all-cause mortality and sudden cardiac death among patients with an EF ≤35% at baseline, with or without an improvement in EF to >35% during follow-up...
July 1, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28721687/practical-approach-to-initiating-sglt2-inhibitors-in-type-2-diabetes
#6
REVIEW
Fernando Gomez-Peralta, Cristina Abreu, Albert Lecube, Diego Bellido, Alfonso Soto, Cristóbal Morales, Miguel Brito-Sanfiel, Guillermo Umpierrez
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure. On the basis of the efficacy demonstrated in clinical trials, SGLT2 inhibitors are recommended as second- or third-line agents for the management of patients with type 2 diabetes...
July 18, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28721152/clinical-syntax-score-a-good-predictor-for-renal-artery-stenosis-in-acute-myocardial-infarction-patients-analysis-from-the-ren-acs-trial
#7
Alexandru Burlacu, Dimitrie Siriopol, Ionut Nistor, Luminita Voroneanu, Igor Nedelciuc, Cristian Statescu, Adrian Covic
INTRODUCTION: In ST-elevation myocardial infarction (STEMI) patients, multisite artery disease represents a serious issue influencing evolution, outcomes and prognosis. We evaluated for the first time the power of the Myocardial Infarction SYNTAX Score (MI SS) and Clinical SYNTAX Score (MI CSS) as predictors for renal artery stenosis (RAS) in STEMI. We also stratified the study population according to the two scores, and identified the variables correlated with the higher score. MATERIAL AND METHODS: We used data from the REN-ACS study, which included 181 consecutive patients prospectively investigated for presence of RAS (through renal angiography), arterial stiffness (carotid-femoral pulse wave velocity, cf-PWV) and hydration status (bioimpedance)...
June 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28712955/clinical-impact-of-changes-in-hemodynamic-indices-of-contractile-function-during-treatment-of-acute-decompensated-heart-failure
#8
Kenneth C Bilchick, Eliany Mejia-Lopez, Peter McCullough, Khadijah Breathett, Jamie L Kennedy, Jose Tallaj, James Bergin, Salpy Pamboukian, Mohammad Abuannadi, Sula Mazimba
BACKGROUND: The objective was to determine the impact of improving right ventricular versus left ventricular stroke work indices (RVSWI v. LVSWI) during therapy for acute decompensated heart failure (ADHF). METHODS AND RESULTS: Cox proportional hazards regression and logistic regression was used to analyze key factors associated with outcomes in 175 patients (age 56.7 ± 13.6 years, 29.1% female) with hemodynamic data from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial...
July 13, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28712629/the-prime-diabetes-model-novel-methods-for-estimating-long-term-clinical-and-cost-outcomes-in-type-1-diabetes-mellitus
#9
William J Valentine, Richard F Pollock, Rhodri Saunders, Jay Bae, Kirsi Norrbacka, Kristina Boye
BACKGROUND: Recent publications describing long-term follow-up from landmark trials and diabetes registries represent an opportunity to revisit modeling options in type 1 diabetes mellitus (T1DM). OBJECTIVES: To develop a new product-independent model capable of predicting long-term clinical and cost outcomes. METHODS: After a systematic literature review to identify clinical trial and registry data, a model was developed (the PRIME Diabetes Model) to simulate T1DM progression and complication onset...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28711446/clinical-effectiveness-of-hydralazine-isosorbide-dinitrate-in-african-american-patients-with-heart%C3%A2-failure
#10
Boback Ziaeian, Gregg C Fonarow, Paul A Heidenreich
OBJECTIVES: This study sought to evaluate the effectiveness of hydralazine-isosorbide dinitrate (H-ISDN) in African Americans with heart failure (HF) with reduced ejection fraction (HFrEF). BACKGROUND: Among African-American patients with HFrEF, H-ISDN was found to improve quality of life and lower HF-related hospitalization and mortality rates in the A-HEFT (African-American Heart Failure Trial). Few studies have evaluated the effectiveness of this therapy in clinical practice...
July 6, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28710537/cardiac-safety-of-non-anthracycline-trastuzumab-based-therapy-for-her2-positive-breast-cancer
#11
Anthony F Yu, Roy B Mukku, Shivani Verma, Jennifer E Liu, Kevin C Oeffinger, Richard M Steingart, Clifford A Hudis, Chau T Dang
PURPOSE: Trastuzumab improves overall survival for women with HER2-positive breast cancer but is associated with cardiotoxicity, especially when administered after anthracyclines. Use of non-anthracycline trastuzumab-based regimens is rising, particularly for patients with low-risk disease or with multiple cardiovascular risk factors. We performed a single-center retrospective cohort study to assess the cardiac safety of trastuzumab without anthracyclines outside of a clinical trial setting...
July 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28709719/metformin-effects-on-the-heart-and-the-cardiovascular-system-a%C3%A2-review-of-experimental-and-clinical-data
#12
REVIEW
L Nesti, A Natali
BACKGROUND: Metformin, the eldest and most widely used glucose lowering drug, is likely to be effective also on cardiac and vascular disease prevention. Nonetheless, uncertainty still exists with regard to its effects on the cardiovascular system as a whole and specifically on the myocardium, both at the organ and cellular levels. METHODS: We reviewed the available data on the cardiac and vascular effects of metformin, encompassing both in vitro, either tissue or isolated organ, and in vivo studies in experimental animals and humans, as well as the evidence generated by major clinical trials...
May 10, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28709650/anticoagulation-control-in-warfarin-treated-patients-undergoing-cardioversion-of-atrial-fibrillation-from-the-edoxaban-versus-enoxaparin-warfarin-in-patients-undergoing-cardioversion-of-atrial-fibrillation-trial
#13
Gregory Y H Lip, Naab Al-Saady, James Jin, Ming Sun, Michael Melino, Shannon M Winters, Dmitry Zamoryakhin, Andreas Goette
In the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) study (NCT 02072434), edoxaban was compared with enoxaparin-warfarin in 2,199 patients undergoing electrical cardioversion of nonvalvular atrial fibrillation (AF). In this multicenter prospective randomized open blinded end-point trial, we analyzed patients randomized to enoxaparin-warfarin. We determined time to achieve therapeutic range (TtTR); time in therapeutic range (TiTR); their clinical determinants; relation to sex, age, medical history, treatment, tobacco use, race risk (SAMe-TT2R2) score; and impact on primary end points (composite of stroke, systemic embolic event[SEE], myocardial infarction [MI], and cardiovascular death [CVD] and composite of major + clinically relevant nonmajor bleeding)...
June 15, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28708290/rationale-and-design-of-the-adaptresponse-trial-a-prospective-randomized-study-of-cardiac-resynchronization-therapy-with-preferential-adaptive-left-ventricular-only-pacing
#14
Gerasimos Filippatos, David Birnie, Michael R Gold, Bart Gerritse, Ahmad Hersi, Sandra Jacobs, Kengo Kusano, Christophe Leclercq, Wilfried Mullens, Bruce L Wilkoff
The AdaptResponse trial is designed to test the hypothesis that preferential adaptive left ventricular-only pacing with the AdaptivCRT(®) algorithm reduces the incidence of the combined endpoint of all-cause mortality and intervention for heart failure (HF) decompensation, compared with conventional cardiac resynchronization therapy (CRT), among patients with a CRT indication, left bundle branch block (LBBB) and normal atrioventricular (AV) conduction. The AdaptResponse study is a prospective, randomized, controlled, single-blinded, multicentre, clinical trial (ClinicalTrials...
July 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28706575/targeting-endothelial-function-to-treat-heart-failure-with-preserved-ejection-fraction-the-promise-of-exercise-training
#15
REVIEW
Andreas B Gevaert, Katrien Lemmens, Christiaan J Vrints, Emeline M Van Craenenbroeck
Although the burden of heart failure with preserved ejection fraction (HFpEF) is increasing, there is no therapy available that improves prognosis. Clinical trials using beta blockers and angiotensin converting enzyme inhibitors, cardiac-targeting drugs that reduce mortality in heart failure with reduced ejection fraction (HFrEF), have had disappointing results in HFpEF patients. A new "whole-systems" approach has been proposed for designing future HFpEF therapies, moving focus from the cardiomyocyte to the endothelium...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28705321/implantable-hemodynamic-monitoring-for%C3%A2-heart-failure-patients
#16
REVIEW
William T Abraham, Leor Perl
Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure-guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach...
July 18, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28705314/palliative-care-in-heart-failure-the-pal-hf-randomized-controlled-clinical-trial
#17
Joseph G Rogers, Chetan B Patel, Robert J Mentz, Bradi B Granger, Karen E Steinhauser, Mona Fiuzat, Patricia A Adams, Adam Speck, Kimberly S Johnson, Arun Krishnamoorthy, Hongqiu Yang, Kevin J Anstrom, Gwen C Dodson, Donald H Taylor, Jerry L Kirchner, Daniel B Mark, Christopher M O'Connor, James A Tulsky
BACKGROUND: Advanced heart failure (HF) is characterized by high morbidity and mortality. Conventional therapy may not sufficiently reduce patient suffering and maximize quality of life. OBJECTIVES: The authors investigated whether an interdisciplinary palliative care intervention in addition to evidence-based HF care improves certain outcomes. METHODS: The authors randomized 150 patients with advanced HF between August 15, 2012, and June 25, 2015, to usual care (UC) (n = 75) or UC plus a palliative care intervention (UC + PAL) (n = 75) at a single center...
July 18, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28704280/the-paradox-of-transient-worsening-renal-function-in-patients-with-acute-heart-failure-the-role-of-b-type-natriuretic-peptide-and-diuretic-response
#18
Gaetano Ruocco, Ranuccio Nuti, Amalia Giambelluca, Isabella Evangelista, Oreste De Vivo, Cosimo Daniello, Alberto Palazzuoli
AIMS: Worsening renal function (WRF) occurs in one-third of patients hospitalized for acute decompensated heart failure. Recently, WRF was categorized in two subtypes: persistent and transient WRF. Thus, we sought to investigate the different prognostic impact of persistent vs. transient WRF; we also evaluate the relation of two WRF phenotypes with congestion, B-type natriuretic peptide (BNP) changes, and diuretic response at discharge. METHODS: The prospective was a single centre study including patients screened for interventional Diur-heart failure Trial (NCT01441245)...
July 12, 2017: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/28702858/effect-of-renin-angiotensin-system-inhibitors-on-mortality-in-heart-failure-with-preserved-ejection-fraction-a-meta-analysis-of-observational-cohort-and-randomized-controlled-studies
#19
REVIEW
Hidekatsu Fukuta, Toshihiko Goto, Kazuaki Wakami, Nobuyuki Ohte
Despite the high mortality rate, there is no therapy to improve survival in heart failure with preserved ejection fraction (HFpEF). Large randomized controlled trials (RCTs) did not show clear mortality benefit of renin-angiotensin system (RAS) inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) in HFpEF. However, because of the strict enrollment criteria, the patients who participated in these trials might represent a selected group of patients that is poorly representative of patients treated in routine clinical practice...
July 12, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/28701888/pharmacological-treatment-of-heart-failure-with-preserved-ejection-fraction
#20
REVIEW
Kazuhiro Yamamoto
Heart failure with preserved ejection fraction is a socioeconomic burden in Japan as well as other developed countries. Diuretics are widely used to attenuate symptoms and signs of congestion in both heart failure with preserved and reduced ejection fraction, although their effects on long-term prognosis of both phenotypes of heart failure have not been demonstrated because of an ethical difficulty in designing a randomized and prospective clinical trial. Guidelines do not provide any guidance on therapy choice, and physicians blindly choose furosemide among loop diuretics in current clinical settings...
June 2017: Yonago Acta Medica
keyword
keyword
102723
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"